In drugtreatmentsforpms 1992 in El Paso, TX a randomized, double-blind, placebo controlled study of subjects (n=130) with allergic rhinitis in 1992-1993 was conducted. The average IgE level of the placebo treated subjects remained essentially flat, drugtreatmentsforpms while the average IgE level for active treated subjects was reduced significantly from baseline to Day 30.7 In 1993 in El Paso, TX, valid subjects (n=66) returned a second set of symptom diaries which they had completed for days 365 to 395 (the same period, one year after the first set of symptom diaries). The active group had mean symptom scores showing statistically significant decreases from 1992 to 1993. The placebo group had increased symptoms in 1993. (The relevant pollen counts at the study site in 1993 were much higher than in 1992, leading to expectation of higher symptoms.)7

With drugtreatmentsforpms no further treatment, the 1996 drugtreatmentsforpms ten-month drugtreatmentsforpms follow-up data (n=92) from a high pollen period in Oregon, Washington and Idaho together showed a greater reduction in the active group (n=43) than the placebo group (n=49) on the primary endpoint, defined as a combination of symptom and rescue medication scores.8 Patients gave blood serum samples prior to the treatment in 1995 drugtreatmentsforpms and drugtreatmentsforpms and one year later in 1996. They were immunoassayed for specific IgE antibodies using a chemi-luminescent technique. Statistician drugtreatmentsforpms Bradley Rosebrook ran T-Tests comparing average baseline IgE levels to one-year. For the seasonal allergens reported, the active group (n=27) drugtreatmentsforpms had on average a greater reduction in IgE than the placebo group (n=34) for 13 out of 16 allergens.8

©2003 www.female-prenatal-supplements.com All rights reserved.